top of page

Psychedelic Research in the Land

Active Clinical Trials:

Published: 

From Taboo to Treatment: The Emergence of Psychedelics in the Management of Pain and Opioid Use Disorder.
Jeremy Weleff, Julio Nunes, Gabriel Costa, et al.
October 30th, 2023
Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.
Barnett BS, Bassir Nia A, Sackett NB and Weleff J
October 19th 2023
Psychedelic Commercialization: A Wide-Spanning Overview of the
Emerging Psychedelic Industry
Jacob S. Aday, Brian S. Barnett, Dan Grossman, Kevin S. Murnane, Charles D. Nichols, and Peter S. Hendricks
September 2023
American Psychiatrists' Opinions About Classic
Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.
Brian S. Barnett, Miranda Arakelian, David Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, and Harrison G. Pope.
September 2023
Perceived risk of LSD use in the United States from
2015-2019: Are Americans assessing LSD’s risk profile more favorably?
Barnett BS, Anand A, Dewey EN, et al
September 2023
Bibliometric Analysis of Academic Journal Articles Reporting
Results of Psychedelic Clinical Studies.
Weleff J, Akiki TJ, Barnett BS
September 2023
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Kovacevich A, Weleff J, Claytor B, Barnett BS
August 31st, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B.
June 22, 2023
Case report: Prolonged amelioration of
mild red-green color vision deficiency following psilocybin mushroom use.
Barnett, B. S., Sweat, N. W., & Hendricks, P. S.
May 2, 2023
Psychedelic Medicine's Future Depends on Proactive
Development of a Robust Medical Billing and Coding Strategy
Brian S. Barnett and Andrey Ostrovsky.
March 2023
LSD use in the United States: Examining user demographics and their evolution from 2015-2019.
Weleff, J., Anand, A., Dewey, E., & Barnett, B.
December 2022
The perceptions of cancer health-care
practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey.
Reynolds LM, Barnett B, Weleff J, Morunga E, Wells A, Stack A, Akroyd A, Hoeh N, Sundram F, Muthukumaraswamy S, Lawrence N, Evans WJ.
November 3rd 2022
Is psychedelic use associated with cancer?:
Interrogating a half-century-old claim using contemporary population-level data.
Barnett BS, Ziegler K, Doblin R, Carlo AD
October 2022
Deepening our understanding of psychedelics by expanding psychedelic data
collection in the United States National Survey on Drug Use and Health
Barnett BS
October 2022
Psychedelic Knowledge and Opinions in
Psychiatrists at Two Professional Conferences: An Exploratory Survey.
Barnett BS, Beaussant Y, King F 4th, Doblin R.
Jul-Aug 2022
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020
Barnett BS, Parker SE, Weleff J
January 2022
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
Barnett BS, Greer GR.
Jul-Aug 2021
bottom of page